epivax analysis of ebolavirus zaire ebolavirus - mayinga (the current ebola outbreak strain)

EpiVax Analysis of Ebolavirus Zaire Ebolavirus - Mayinga

(the current Ebola Outbreak Strain)

An Immunoinformatics data set for Ebola

Vaccine Developers

Compiled using EpiVax State of the Art tools.

For more information see http://bit.ly/

EpiVax_Vaccine

•  Biotech company based in Providence, Rhode Island •  Owned and operated by Annie De Groot and Bill Martin

Who are We? (EpiVax)

2

EpiVax designs and develops safer, more effective biologic

products and vaccines

Engaged

Dedicated to improving human health everywhere

Cutting Edge

Continuously innovating thought leaders in immunoinformatics

Trusted

Highly Published Trusted by majority of large

Pharma companies EpiVax -‐ Non-‐non-‐confiden1al 2

2014 West Africa Ebola Outbreak Rapidly Expanding Lethal Virus Outbreak

8/17/14 non-‐confiden1al 3

http://www.cdc.gov/vhf/ebola/resources/distribution-map-guinea-outbreak.html

•  Four countries affected: Sierra Leone, Liberia, Guinea, Nigeria

•  As of Aug. 15th 2014: –  Suspected and Confirmed Case Count: >2000 –  Suspected Case Deaths: >1000 –  Mortality Rate: >50%

•  No known cure •  No available vaccine

2014 West Africa Outbreak Statistics


http://www.cdc.gov/vhf/ebola/outbreaks/guinea/

How Can We Help?

•  IVAX is a key tool in designing effective vaccines in a rational, efficient manner

•  Already providing access to iVAX toolkit to our commercial and academic collaborators

•  We can rapidly analyze Ebola for optimal vaccine components

•  Perhaps this will be helpful for better design of Ebola vaccines, making it available to the scientific public is what we can do to help.

•  Any questions – please contact [email protected] EpiVax -‐ Non-‐non-‐confiden1al 5

Why are we releasing findings online: •  EpiVax has unique technology for designing vaccines. •  The techology accurately predicted the high immunogenicity of pandemic H1N1 (only one dose of vaccine needed, most individuals protected by seasonal flu exposure) h^p://bit.ly/Pandemic_H1N1

•  The techology accurately predicted H7N9 low immunogenicity “Stealth virus”. h^p://bit.ly/H7N9_Stealth

•  We would like to make our contribu1on to stopping Ebola by making our immunoinforma1cs analysis of the current virus available world-‐wide.

EpiVax Contributes to Stopping Ebola


iVAX – Quick Facts

EpiVax -‐ Non-‐non-‐confiden1al 7

•  Comprehensive set of vaccine design tools •  Flexible utilization – vaccine design, antigen

engineering, vaccine efficacy analysis •  Applications to assay reagent development and

diagnostics (ELISpot assays, e.g.) •  Compatible with modular tool development (ex

insertion of tools for animal vaccine design) •  Interactive web access anytime •  Involved training program and technical service

h^p://bit.ly/EpiPubs 8

iVAX Toolkit – Commercial

EpiVax -‐ Non-‐non-‐confiden1al

iVAX Toolkit – Academic

9

10

Vaccine Design Tools and Techniques

Epitope/Antigen Analysis and Discovery

Vaccine Construct Design/ Optimization

Lab Validation

10

JanusMatrix: Analyze T cell epitope cross-reactivity

TB Epitope Discovery

Epitope Validation

Construct Design

Immuno-genicity

Tularemia Epitope Discovery

Epitope Validation

Construct Design

Immuno-genicity

Animal Model Validation

Smallpox Epitope Discovery

Epitope Validation

Construct Design


HCV Epitope Discovery

Epitope Validation

Construct Design


H. pylori Epitope Discovery

Epitope Validation

Construct Design



Immuno-genicity

Immuno-genicity

Immuno-genicity

EpiVax Vaccine Design Pipeline HIV Epitope

Discovery Epitope

Validation Construct

Design Immuno-genicity


Influenza Epitope Discovery

Epitope Validation

Construct Design

Immuno-genicity


VEEV/EEV Epitope Discovery

Epitope Validation

Construct Design

Immuno-genicity


Burkholderia Epitope Discovery

Epitope Validation

Construct Design

Immuno-genicity


Selected publications:

12

Publications related to Vaccines 2013-2014 Lu He, Anne S De Groot, Andres H Gutierrez, William D Martin, Lenny Moise and Chris Bailey-Kellogg. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics 2014, 15 (Suppl 4): S1 doi:10.1186/1471-2105-15-S4-S1. http://bit.ly/Viral_Camouflage_2014. Zhang S, Desrosiers J, Aponte-Pieras JR, Dasilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss SF. Human Immune Responses to H. pylori HLA Class II Epitopes Identified by Immunoinformatic Methods, PLoS One. 2014 Apr 16;9(4):e94974. doi: 10.1371/journal.pone.0094974. eCollection 2014. PMID: 24740005 [PubMed - in process]. http://bit.ly/HPylori_PLOS_One_2014 De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. Hum Vaccin Immunother. 2014 Feb;10(2):256-62. doi: 10.4161/hv.28135. Epub 2014 Feb 13. PMID: 24525618 [PubMed - in process]. http://bit.ly/H7N9_Stealth Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, Verberkmoes N, Sztein MB, Losikoff P, Martin WD, Rothman A, De Groot AS. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013 Apr 12;9(7). PubMed PMID 23584251. De Groot AS, Ardito M., Terry, F. Levitz L., Ross T., Moise L., Martin B. Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design. Hum Vaccin Immunother. Volume 9, Issue 5 May 2013:950–956 http://dx.doi.org/10.4161/hv.24939 http://bit.ly/H7N9_2013. http://bit.ly/H7N9_HVandI. Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD. Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Human Vaccines & Immunotherapeutics 2013; 9:1598 - 1607; PMID: 23846304; http://dx.doi.org/10.4161/hv.25598


13

Publications related to Vaccines 2013-2014 Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q. Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease. Virus Res. 2013 Jul 22. doi:pii: S0168-1702(13)00231-1. 10.1016/j.virusres.2013.07.009. Leonard Moise, Ryan Tassone, Howard Latimer, Frances Terry, Lauren Levitz, John P. Haran, Ted M. Ross, Christine Boyle, William D. Martin, Anne S. De Groot. Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice. Hum Vaccin Immunother. 2013 Sep 17;9(10). http://bit.ly/H1N1_DR3_2014 Review. Moise L., Marcello, A, Tassone, R., Cousens, L., Martin, W., De Groot, A.S., Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company. Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf Proceedings. He Y, Cao Z, De Groot AS, Brusic V, Schönbach C, Petrovsky N. Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics. 2013;14 Suppl 4:I1.doi: 10.1186/1471-2105-14-S4-I1. Epub 2013 Mar 8. PubMed PMID: 23514034; PubMed Central PMCID: PMC3599086. Review. De Groot AS, Einck L., Moise L, Chambers M., Ballantyne J., Malone RW, Ardito M, Martin W. Making Vaccines “On Demand”: A Potential Solution for Emerging Pathogens and Biodefense? Human Vaccines and Immunotherapy. Accepted for publication June 27, 2013. http://bit.ly/FastVax Leonard Moise, Frances Terry, Andres H. Gutierrez, Ryan Tassone, Phyllis Losikoff, Stephen H. Gregory, Chris Bailey-Kellogg, William D. Martin, Anne S. De Groot. Time for T? Immunoinformatics addresses the challenges of vaccine design for neglected tropical and emerging infectious diseases. Expert Review of Vaccines, Accepted 3 Aug 2014. Opinion. Anne S. De Groot, Lenny Moise, Rui Liu, Andres H. Gutierrez, Ryan Tassone, Chris Bailey-Kellogg, William Martin. Immune Camouflage: Relevance to Vaccine Design and Human Immunology Submitted 3 Aug 2014, July 2014, Human Vaccines and Immunotherapy. Moise L, Terry F, Gutierrez AH, Tassone R, Losikoff P, Gregory SH, Martin WD, De Groot AS. Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. In: Why vaccines to HIV, HCV and Malaria have so far failed - challenges to developing vaccines against immunoregulating pathogens. Accepted August 15 2014. Frontiers in Microbiology. 2014. Editor (Gowans).


14

Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q. Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease. Virus Res. 2013 Jul 22. doi:pii: S0168-1702(13)00231-1. 10.1016/j.virusres.2013.07.009. Leonard Moise, Ryan Tassone, Howard Latimer, Frances Terry, Lauren Levitz, John P. Haran, Ted M. Ross, Christine Boyle, William D. Martin, Anne S. De Groot. Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice. Hum Vaccin Immunother. 2013 Sep 17;9(10). http://bit.ly/H1N1_DR3_2014 Moise L., Marcello, A, Tassone, R., Cousens, L., Martin, W., De Groot, A.S., Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company. Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf He Y, Cao Z, De Groot AS, Brusic V, Schönbach C, Petrovsky N. Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics. 2013;14 Suppl 4:I1.doi: 10.1186/1471-2105-14-S4-I1. Epub 2013 Mar 8. PubMed PMID: 23514034; PubMed Central PMCID: PMC3599086. De Groot AS, Einck L., Moise L, Chambers M., Ballantyne J., Malone RW, Ardito M, Martin W. Making Vaccines “On Demand”: A Potential Solution for Emerging Pathogens and Biodefense? Human Vaccines and Immunotherapy. Accepted for publication June 27, 2013. http://bit.ly/FastVax Leonard Moise, Frances Terry, Andres H. Gutierrez, Ryan Tassone, Phyllis Losikoff, Stephen H. Gregory, Chris Bailey-Kellogg, William D. Martin, Anne S. De Groot. Time for T? Immunoinformatics addresses the challenges of vaccine design for NT and EID. Expert Review of Vaccines, Accepted 3 Aug 2014. Opinion. Anne S. De Groot, Lenny Moise, Rui Liu, Andres H. Gutierrez, Ryan Tassone, Chris Bailey-Kellogg, William Martin. Immune Camouflage: Relevance to Vaccine Design and Human Immunology Submitted 3 Aug 2014, July 2014, Human Vaccines and Immunotherapy. Moise L, Terry F, Gutierrez AH, Tassone R, Losikoff P, Gregory SH, Martin WD, De Groot AS. Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. In: Why vaccines to HIV, HCV and Malaria have so far failed - challenges to developing vaccines against immunoregulating pathogens. Accepted August 15 2014. Frontiers in Microbiology. 2014. Editor (Gowans).

Steps to Vaccine Design

•  Define Pathogen (genome, diagnostic test) •  Correlates of Immunity? •  Critical Antigens - one or many? •  Animal Model? Does it predict protection? •  Prototype Vaccine - Preclinical Proof •  Safety and Toxicity, GMP, Stability •  FDA “IND” (Investigational New Drug) •  Clinical trials (Phase I, II, III) •  FDA Approval /Distribution / Access


Steps to vaccine design

•  Define Pathogen (genome, diagnostic test) •  Correlates of Immunity? •  Critical Antigens - one or many? •  Animal Model? Does it predict protection? •  Prototype Vaccine - Preclinical Proof •  Safety and Toxicity, GMP, Stability •  FDA “IND” (Investigational New Drug) •  Clinical trials (Phase I, II, III) •  FDA Approval /Distribution / Access


•  RNA virus, member of the Filoviridae family (composed of the Cuevavirus, Ebolavirus, and Marburgvirus genera)

•  Ebolavirus contains seven genes: 3’ – leader – NP – VP35 – VP40 – GP/sGP – VP30 – VP24 – L – tailer – 5’

•  GP is the sole protein expressed at the surface of the virus

•  GP is likely to be a good candidate for vaccines

Ebolavirus Structure


•  Circula1ng strain: Zaire Ebolavirus

Ebolavirus Circulating strain


•  Uniprot contains data for 16 Filoviridae strains:

Filoviridae


Code Strain EBOEC Zaire ebolavirus (strain Eckron-‐76) EBOG4 Zaire ebolavirus (strain Gabon-‐94) EBOIC Ivory Coast ebolavirus (strain Cote d'Ivoire-‐94) EBORE Reston ebolavirus (strain Philippines-‐96) EBORR Reston ebolavirus (strain Reston-‐89) EBORS Reston ebolavirus (strain Siena/Philippine-‐92) EBOSB Sudan ebolavirus (strain Boniface-‐76) EBOSM Sudan ebolavirus (strain Maleo-‐79) EBOSU Sudan ebolavirus (strain Uganda-‐00) EBOZ5 Zaire ebolavirus (strain Kikwit-‐95) EBOZM Zaire ebolavirus (strain Mayinga-‐76) <strain that is analyzed here MABVA Lake Victoria marburgvirus (strain Angola/2005) MABVM Lake Victoria marburgvirus (strain Musoke-‐80) MABVO Lake Victoria marburgvirus (strain Ozolin-‐75) MABVP Lake Victoria marburgvirus (strain Popp-‐67) MABVR Lake Victoria marburgvirus (strain Ravn-‐87)

•  Data was obtained from Uniprot •  Filoviridae reference dataset was downloaded by searching

the Protein Knowledgebase (UniProtKB) (query: taxonomy:11266 AND reviewed:yes)

•  97 retrieved sequences, by protein:

non-confidential 20

iVax Analysis of Ebola virus Data Retrieval

8/17/14

Protein Count Protein Count

NP 12 ssGP 5

VP35 10 VP30 10

VP40 11 VP24 11

GP 16 L 11

sGP 11

“Immunogenicity Scale”

h^p://bit.ly/EpiPubs

21

The number of T cell epitopes contained in the sequence of a protein contributes to its immunogenicity

Proteins can be compared based on T cell epitope content per unit sequence.

EpiVax - Non-non-confidential 21

gB-2 (EPX Score: -24.56)

- 80 -

- 70 -

- 60 -

- 50 -

- 40 -

- 30 -

- 20 -

- 10 -

- 00 -

- -10 -

- -20 -

- -30 -

- -40 -

- -50 -

- -60 -

- -70 -

- -80 -

Thrombopoietin

Human EPO

Tetanus Toxin

Influenza-HA

Albumin

IgG FC Region

EBV-BKRF3

Fibrinogen-Alpha

Follitropin-Beta

HA A/California/07/2009 (H1N1)

HA A/Victoria/361/2011 (H3N2)

HA A/Texas/50/2012 (H3N2)

HA A/Anhui/1/2013 (H7N9) HA A/mallard/Netherlands/09/2005 (H7N7)

Random ExpectaOon

HA A/mallard/Netherlands/12/2000 (H7N3)

HA A/chicken/Italy/13474/1999 (H7N1)

H7 HA Immunogenic PotenOal

New H7N9 Flu is Predicted to be POORLY IMMUNOGENIC

http://bit.ly/H7N9_HVandI

iVax Analysis of Ebola virus Class II Analysis


•  Immunogenicity scale of Zaire Ebolavirus – Mayinga proteins (with EpiMatrix scores) – Red is high poten1al, blue is low.

Excellent candidate

Poor candidate

Theore1cal minimum an1genicity

score

PotenOal Ags Ebola Zaire

- 80 -

- 70 -

- 60 -

- 50 -

- 40 -

- 30 -

- 20 -

- 10 -

- 00 -

- -10 -

- -20 -

- -30 -

- -40 -

- -50 -

- -60 -

- -70 -

- -80 -

Albumin

IgG FC Region Fibrinogen-Alpha

Tetanus Toxin

Influenza H3N1-HA

GP_EBOZM (-14.74)

L_EBOZM (34.64)

NP_EBOZM (-12.17)

SGP_EBOZM (6.03) SSGP_EBOZM (11.84)

VP24_EBOZM (95.68)

VP30_EBOZM (5.73)

VP35_EBOZM (-22.18) VP40_EBOZM (-18.01)

Influenza H7N9-HA

EBV-BKRF3

HBV S Ag

EpiVax - Non-non-confidential 25

ClustiMer – finds “hot spots”

DRB1*0101

DRB1*0301

DRB1*0401

DRB1*0701

DRB1*0801

DRB1*1101

DRB1*1301

DRB1*1501

•  T cell epitopes are not randomly distributed but instead tend to cluster in specific regions. –  These clusters can be very powerful, enabling significant immune responses to low scoring

proteins.

•  Clus1Mer recognizes T-‐cell epitope clusters as polypep1des predicted to bind to an unusually large number of HLA alleles.

•  T-‐cell epitope clusters make excellent vaccine candidates:

–  compact; rela1vely easy to deliver as pep1des; highly reac1ve in-‐vivo

iVax Analysis of Ebola virus Class II Analysis – Clusters promiscuous epitopes


•  Clusters iden1fied for Zaire Ebolavirus – Mayinga proteins

Protein Code # clusters

NP NP_EBOZM 14

VP35 VP35_EBOZM 5

VP40 VP40_EBOZM 7

GP GP_EBOZM 16

sGP SGP_EBOZM 12

ssGP SSGP_EBOZM 10

VP30 VP30_EBOZM 8

VP24 VP24_EBOZM 9

L L_EBOZM 62



•  Immunogenic clusters found by Clus1Mer in Zaire Ebolavirus – Mayinga



•  EpiMatrix scores of GP’s immunogenic clusters



•  Removed clusters with no EpiBar or high hydrophobicity (EpiVax standard approach)



•  Immunogenicity scale of clusters found in Zaire Ebolavirus – Mayinga GP protein

Tetanus Toxin (825-850)

HCV NPC NS3 (1248-1267)

Influenza HA (306-319)

Tetanus Toxin (947-967)

Human CLIP

EBV BHRF1(171-189)

20-mer Theoretical Minimum

-  +40 -

-  -

-  +30 -

-  -

-  +20 -

-  -

-  +10 -

-  -

-  0.0 -

-  -

-  -10 -

PROTEIN ADDRESS SCORE

GP_EBOZM 16 – 38 47.6

GP_EBOZM 245 – 265 28.17

GP_EBOZM 566 – 583 22.55

GP_EBOZM 579 – 595 20.25

GP_EBOZM 32 – 49 18.95 GP_EBOZM 156 – 174 17.4

GP_EBOZM 336 – 352 15.84

GP_EBOZM 85 – 99 15.38

GP_EBOZM 238 – 252 13.8

GP_EBOZM 190 – 204 11.22

GP_EBOZM 555 – 569 10.5

GP_EBOZM 215 – 229 10.05

NOT SHOWN ON SCALE



•  EpiMatrix report of GP, cluster 16

•  Homology search of GP, cluster 16 •  Conserva1on among the Filoviridae genus (excluding Zaire

Ebolavirus – Mayinga), 15 maximum hits




8/17/14 non-‐non-‐confiden1al 54


Cluster EPX score

# epitopes TCR-‐facing residues conservaOon (1)

Human cross-‐reacOvity (2)

Microbiome cross-‐reacOvity (3)

GP_EBOZM:16 47.6 3 20 % 0 -‐ 4 15 – 43 GP_EBOZM:32 18.95 1 20 % 5 17 GP_EBOZM:85 15.38 1 47 % 0 9 GP_EBOZM:156 17.43 2 60 -‐ 67 % 0 -‐ 2 10 – 19 GP_EBOZM:190 11.22 1 20 % 0 25 GP_EBOZM:215 10.05 1 20 % 1 12

iVax Analysis of Ebola virus Class II Analysis – Conservation wth Human etc.


The table displays ranges in the case a cluster contains several epitopes. (1) % of Filoviridae strains with similar TCR-facing residues to the ones in Zaire Ebolavirus – Mayinga epitopes (2) Number of human sequences with similar TCR-facing residues to the ones in Zaire Ebolavirus – Mayinga epitopes (3) Number of human microbiome sequences with similar TCR-facing residues to the ones in Zaire Ebolavirus – Mayinga epitopes

•  Cross-‐reac1vity analysis of GP clusters (JanusMatrix analysis)

Cluster EPX score

# epitopes TCR-‐facing residues conservaOon (1)

Human cross-‐reacOvity (2)

Microbiome cross-‐reacOvity (3)

GP_EBOZM:238 13.8 1 27 % 2 6 GP_EBOZM:245 28.17 2 13 -‐ 20 % 0 -‐ 16 12 – 139 GP_EBOZM:336 15.84 1 20 % 2 12 GP_EBOZM:555 10.5 1 67 % 0 31 GP_EBOZM:566 22.55 2 67 % 3 -‐ 8 76 – 49 GP_EBOZM:579 20.25 1 27 % 2 21

iVax Analysis of Ebola virus Class II Analysis – Conservation wth Human etc.


The table displays ranges in the case a cluster contains several epitopes. (1) % of Filoviridae strains with similar TCR-facing residues to the ones in Zaire Ebolavirus – Mayinga epitopes (2) Number of human sequences with similar TCR-facing residues to the ones in Zaire Ebolavirus – Mayinga epitopes (3) Number of human microbiome sequences with similar TCR-facing residues to the ones in Zaire Ebolavirus – Mayinga epitopes

•  Cross-‐reac1vity analysis of GP clusters (JanusMatrix analysis)

•  Zaire Ebolavirus – Mayinga surface protein, GP, has a low immunogenic poten1al at the protein level

•  iVAX iden1fied 16 clusters of immunogenicity in the GP sequence

•  Several clusters present: –  High EpiMatrix scores –  High degree of conserva1on among Filoviruses –  Low degree of cross-‐reac1vity to human and human microbiome

sequences

iVax Analysis of Ebola virus Class II Analysis – Summary


•  Zaire Ebolavirus – Mayinga surface protein, GP, has a low immunogenic poten1al at the protein level

•  iVAX iden1fied 16 clusters of immunogenicity in the GP sequence

•  From these, three (Cluster 85, Cluster 150, and Cluster 555) present proper1es interes1ng for vaccine development: –  High EpiMatrix scores –  High degree of conserva1on among Filoviruses –  Low degree of cross-‐reac1vity to human and human microbiome

sequences

iVax Analysis of Ebola virus Class II Analysis – Summary


•  EpiMatrix scores of Zaire Ebolavirus – Mayinga proteins (data parsed in 9-‐mers)

iVax Analysis of Ebola virus Class I Analysis


•  EpiMatrix scores of Zaire Ebolavirus – Mayinga proteins (data parsed in 10-‐mers)



•  Immunogenicity screening of Zaire Ebolavirus – Mayinga GP protein

•  iVAX iden1fied 143 9-‐mers and 10-‐mers sequences with increased immunogenic poten1al in regards to at least one HLA Class I allele (HLA-‐A*0101, HLA-‐A*0201, HLA-‐A*0301, HLA-‐A*2402, HLA-‐B*0702, HLA-‐B*4403)

•  From these, 80 sequences present limited homology to human sequences (less than 5 hits)

•  From these, 59 sequences have at least one posi1ve hit and no nega1ve hit in IEDB

Please contact [email protected] for more informa1on.



•  Immunogenicity screening of Zaire Ebolavirus – Mayinga GP protein

iVax Analysis of Ebola virus Class I Analysis for details email [email protected]


143 9-‐mers and 10-‐mers with increased immunogenic poten1al to at least one HLA Class I allele (1)

80 sequences with limited homology to human sequences (less than five hits)

59 sequences with at least one posi1ve hit and no nega1ve hit in IEDB

(1) HLA-A*0101, HLA-A*0201, HLA-A*0301, HLA-A*2402, HLA-B*0702, HLA-B*4403

Vaccine Collaborations

Don Drake Brian Schanen

Sharon Frey Mark Buller Jill Schreiwer

Hardy Kornfeld Jinhee Lee Liisa Selin

Connie Schmaljohn Lesley C. Dupuy

Ted Ross

Mark Poznansky Tim Brauns Pierre LeBlanc

AI058326, AI058376, AI078800, AI082642

h^p://bit.ly/EpiPubs 67

Vish Mokashi Biswajit Biswas

Manon Cox Indresh Srivastava

Manabu Ato Yoshi Takahashi

Drew Hannaman

epivax analysis of ebolavirus zaire ebolavirus - mayinga (the current ebola outbreak strain)

Health & Medicine

h7n9 influenza vaccine

epivax epivax designs

twofaced t cell epitope

ebola vaccine developers

epivax state

optimal vaccine components

current ebola outbreak

martin wd